首页 | 本学科首页   官方微博 | 高级检索  
     


Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII
Authors:M. T. Reding  H. J. Ng  L. H. Poulsen  M. E. Eyster  I. Pabinger  H.‐J. Shin  R. Walsch  M. Lederman  M. Wang  M. Hardtke  L. A. Michaels
Affiliation:1. University of Minnesota Medical Center, Minneapolis, MN, USA;2. Department of Haematology, Singapore General Hospital, Singapore;3. Centre for Haemophilia and Thrombosis, Aarhus University Hospital, Aarhus, Denmark;4. Penn State Hershey Medical Center, Hershey, PA, USA;5. Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria;6. Division of Hematology‐Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Korea;7. Bayer Vital GmbH, Leverkusen, Germany;8. Bayer, Whippany, NJ, USA;9. Bayer Pharma AG, Berlin, Germany
Abstract:
Keywords:clinical trial  factor VIII  hemophilia A  prophylaxis  recombinant proteins
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号